-
公开(公告)号：US10046019B2
公开(公告)日：2018-08-14
申请号：US15261998
申请日：2016-09-11
Applicant: YUNGJIN PHARMACEUTICAL CO., LTD , KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY
Inventor： Yongnam Lee , Ji-seok Yoo , Dae-hee Shin , Byung-hwan Ryoo , Sei-ryang Oh , Kyung-seop Ahn , Hyeongkyu Lee , Ok-kyoung Kwon , Doo-young Kim , Jung-hee Kim , Hyuk-hwan Song
IPC: A61K36/00 , A61K36/68 , A23L1/29 , A61K31/192 , A61K31/7048 , A61K36/80 , A23L27/10 , A23L33/105 , A61K9/00
Abstract: The present invention relates to inventive novel industrialized method for preparing purified extract containing more abundant active ingredients such as catalpol derivatives from the extract of Pseudolysimachion rotundum var subintegrum than that prepared by the conventional preparation method disclosed in the prior art and the therapeutics or functional health food comprising the purified extract for treating and preventing inflammatory, allergic or asthmatic disease. The purified extract showed more potent anti-inflammatory, anti-allergy and anti-asthma activity than that prepared by the conventional preparation method disclosed in the prior art through various in vivo tests such as inhibition test on the reproduction of eosinophil, the release of immunoglobulin and inflammatory chemokines in plasma and bronchoalveolar fluid as well as the suppression of airway hyperresponsiveness and goblet cell hyperplasia in a OVA-sensitized/challenged mouse model.
-
公开(公告)号：US20180133305A1
公开(公告)日：2018-05-17
申请号：US15574274
申请日：2015-09-14
Inventor： Dae Gwin JEONG , Dae Sub SONG , Sun Woo YOON
IPC: A61K39/145 , A61K39/395 , C07K14/11 , C07K16/10 , A61P31/16
CPC classification number: A61K39/145 , A61K39/12 , A61K39/395 , A61K2039/54 , A61K2039/55566 , A61K2039/575 , A61K2039/70 , A61P31/16 , C07K14/005 , C07K14/11 , C07K16/10 , C07K16/1018 , C12N2760/16122 , C12N2760/16134
Abstract: The present invention relates to a versatile influenza virus vaccine composition using the HA2 helical domain of a hemagglutinin protein, which is an influenza surface protein, and to a pharmaceutical composition for preventing or treating influenza virus infectious diseases. The polypeptide expressed by SEQ ID NO: 3 and the polypeptide expressed by residues 379 to 474 of SEQ ID NO: 1 of the present invention can be mass-produced in E. coli, and effectively produce neutralizing antibodies to various influenza virus subtypes, and thus the polypeptides can be widely utilized as versatile vaccines for influenza virus subtypes and new influenza virus variants.
-
33.发明授权公开(公告)号：US09902969B2
公开(公告)日：2018-02-27
申请号：US15319273
申请日：2015-06-16
Inventor： Eun Gyo Lee , Hong-Weon Lee , Shin Young Kang , Yeon-Gu Kim , Joon Ki Jung , Jungoh Ahn , Seung Hee Kang , Chun Sug Kim , Hyeok Won Lee , Jin Gyeom Lee
IPC: C12N15/85 , C12Q1/68 , C07K14/435 , C07K16/00
CPC classification number: C12N15/85 , C07K14/43595 , C07K16/00 , C07K2317/14 , C12N15/63 , C12N2840/203 , C12N2840/60 , C12N2840/85 , C12Q1/68 , C12Q1/6876 , C12Q1/6897
Abstract: The present invention relates to a new gene fragment derived from Chinese hamster ovary (CHO) cell for enhancement of recombinant protein expression in animal cells and a use thereof. It has been found that using the vector comprising a gene fragment of the present invention enhances the expression of a target protein in animal cells. Accordingly, the vector comprising a gene fragment of the present invention could be usefully used in the production of biopharmaceuticals such as therapeutic antibodies, etc.
-
公开(公告)号：US09789114B2
公开(公告)日：2017-10-17
申请号：US15067057
申请日：2016-03-10
Applicant: DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION , KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY
Inventor： Kyeong Lee , Mi-Sun Won , Hwan-Mook Kim , Song-Kyu Park , Ki-Ho Lee , Chang-Woo Lee , Bo-Kyung Kim , Hyun-Seung Ban , Kyung-Sook Chung , Naik Ravi
IPC: A61K31/495 , A61K31/5375 , C07D295/185 , C07D295/073 , C07D241/04 , C07C235/20 , C07C235/22 , C07C231/02 , C07D295/108 , C07D295/182 , C07D487/04 , A61K31/4985 , C07D279/12 , C07D295/104 , C07D307/46
CPC classification number: A61K31/5375 , A61K31/495 , A61K31/4985 , C07C231/02 , C07C235/20 , C07C235/22 , C07D241/04 , C07D279/12 , C07D295/073 , C07D295/104 , C07D295/108 , C07D295/182 , C07D295/185 , C07D307/46 , C07D487/04
Abstract: The present invention relates to novel compounds as HIF-1α inhibitors, manufacturing process thereof, and a pharmaceutical compositions. The compounds according to the present invention having inhibition activity against HIF-1α, can be used as a therapeutic prevention and/or treatment for various solid cancers such as colon cancer, liver cancer, stomach cancer and breast cancer. Also, the compounds according to the present invention are useful in the treatment of diabetic retinopathy and rheumatoid arthritis, which are aggravated by HIF-1α-mediated VEGFA expression.
-
公开(公告)号：US09752190B2
公开(公告)日：2017-09-05
申请号：US14806514
申请日：2015-07-22
Inventor： Jeong Ki Min , Jongjin Park , Kwang-Hee Bae , Sang Chul Lee , Yee Sook Cho
IPC: C07K16/28 , C12Q1/00 , G01N33/50 , C12Q1/68 , G01N33/569
CPC classification number: C12Q1/6881 , C07K16/28 , C12Q2600/158 , G01N33/56966 , G01N2333/705 , G01N2400/00
Abstract: The present invention relates to a composition for detecting the undifferentiated human pluripotent stem cells comprising an agent useful for measuring the level of Desmoglein 2 (Dsg 2) mRNA or the protein thereof, a kit for detecting the undifferentiated human pluripotent stem cells comprising the said composition, a method for detecting the undifferentiated human pluripotent stem cells containing the step of measuring the level of Desmoglein 2 mRNA or the protein thereof, a method for evaluating the differentiation of human pluripotent stem cells and thereafter for separating the undifferentiated human pluripotent stem cells, a method for reducing the undifferentiated status of human pluripotent stem cells by inhibiting the expression or activation of Desmoglein 2, and a monoclonal antibody binding specifically to human Desmoglein 2.
-
Patent Agency Ranking
36.发明申请公开(公告)号：US20170174645A1
公开(公告)日：2017-06-22
申请号：US15449465
申请日：2017-03-03
Applicant: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY , DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
Inventor： Kyeong LEE , Sei-Ryang OH , Kyung Seop AHN , Ok-Kyoung KWON , Doo-Young KIM , Hyung Won RYU , Jung Hee KIM , Xuezhen XU
IPC: C07D307/86 , A23L33/10
CPC classification number: C07D307/86 , A23L33/10 , A23V2002/00 , A61K31/05 , A61K31/343 , C07D307/78 , C07D307/79 , C07D307/80 , C07D307/81
Abstract: The present invention relates to a novel 2-phenylbenzofuran derivative or a pharmaceutically acceptable salt thereof, a production method for the same, and a pharmaceutical composition for preventing or treating an inflammatory disease comprising the same as an active ingredient, and the novel 2-phenylbenzofuran derivative or the pharmaceutically acceptable salt thereof according to the present invention is outstandingly effective in suppressing NO, IL-6, and TNF-alpha induced by macrophages, and therefore can advantageously be used in a pharmaceutical composition for preventing or treating an inflammatory disease.
-
37.发明申请公开(公告)号：US20170173065A1
公开(公告)日：2017-06-22
申请号：US15389248
申请日：2016-12-22
Inventor： Dur Han Kwon , Mi Jin Jang , Jae Hyoung Song , Gansukh Enkhtaivan , Sei Ryang Oh
IPC: A61K31/7056 , A61K9/14 , A61K9/20 , A23L33/10 , A61K9/00 , A23L33/15 , A23L33/135 , A61K31/685 , A61K9/48
CPC classification number: A61K31/7056 , A23L33/10 , A23L33/135 , A23L33/15 , A23V2002/00 , A61K9/0056 , A61K9/14 , A61K9/20 , A61K9/205 , A61K9/48 , A61K9/4866 , A61K31/14 , A61K31/66 , A61K31/6615 , A61K31/685 , A61K31/706 , A61K31/7064 , A61K31/7068 , Y02A50/463 , Y02A50/465
Abstract: The present invention relates to an antiviral composition comprising any one selected from the group consisting of chlorine, phosphocholine, cytidine triphosphate, CDP-choline, phosphorylcholine, and phosphatidylcholine. The antiviral composition is harmless to the human body and exhibits an excellent inhibitory effect on virus proliferation. Therefore, it can be applied to a pharmaceutical composition for preventing or treating viral diseases as well as a health functional food, a quasi-drug composition, and a feed composition for preventing or ameliorating viral diseases.
-
公开(公告)号：US20170112817A1
公开(公告)日：2017-04-27
申请号：US15374225
申请日：2016-12-09
Inventor： Ki Sun Kwon , Sung Sup Park , Sun Gun Chung , Kwang Pyo Lee , Jung Yi Choi
IPC: A61K31/4425
CPC classification number: A61K31/4425 , A61K31/435
Abstract: The present invention relates to A method for promoting the differentiation of myoblasts comprising treating myoblasts with butylpyridinium, a derivative thereof, or a pharmaceutically acceptable salt thereof; a method for strengthening muscles comprising administering butylpyridinium, a derivative thereof, or a pharmaceutically acceptable salt thereof to a subject in need thereof; a feed or feed additive for strengthening muscles comprising butylpyridinium, a derivative thereof, or a pharmaceutically acceptable salt thereof; a method for treating a disease associated with muscle weakness comprising administering butylpyridinium, a derivative thereof, or a pharmaceutically acceptable salt thereof to a subject in need thereof.
-
39.发明申请SIALIC ACID-SPECIFIC BINDING AFFINITY LECTIN FROM THE MUSHROOM HERICIUM ERINACEUM 审中-公开来自MUSHROOM HERIIUM ERINACEUM的酸性特异性结合亲和力公开(公告)号：US20160326223A1
公开(公告)日：2016-11-10
申请号：US15158407
申请日：2016-05-18
Inventor： Seounghun Kim
IPC: C07K14/375 , G01N33/58 , G01N33/68
CPC classification number: C07K14/375 , C07K14/37 , G01N33/582 , G01N33/6848 , G01N2333/42
Abstract: The present invention concerns lectins isolated from the fruiting body of a novel Hericium erinaceum (deposit number: KCTC 12499BP) NEU-1L strain which bind specifically to sialic acid. The invention further pertains to uses of such lectinsn abd to processes for their preparation thereby. The lectin of the present invention can be useful as an active ingredient of a composition or a kit for measuring or detecting glycoproteins, glycopeptides, glycolipids, sugar precursors or oligosaccharides containing sialic acid moieties, or further for measuring or detecting cell lines, bacteria and viruses containing sialoglycoconjugates.
Abstract translation: 本发明涉及从与唾液酸特异性结合的新型Hericium erinaceum（保藏号：KCTC 12499BP）NEU-1L菌株的子实体分离的凝集素。 本发明还涉及这样的凝集素的用途，以便制备其制备方法。 本发明的凝集素可用作用于测量或检测糖蛋白，糖肽，糖脂，糖前体或含有唾液酸部分的寡糖或进一步用于测量或检测细胞系，细菌和病毒的组合物或试剂盒的活性成分 含有sialoglycoconjugates。
-
40.发明授权公开(公告)号：US09482669B2
公开(公告)日：2016-11-01
申请号：US14310879
申请日：2014-06-20
Inventor： Sang Ho Choi , Byoung Sik Kim , Myung Hee Kim , Jung Won Hwang
IPC: G01N33/569 , C07K14/28
CPC classification number: G01N33/56911 , C07K14/28 , G01N2400/00 , G01N2500/04
Abstract: The present invention relates to a three-dimensional structure of a complex explored by crystallization of the complex of NanR which is a key pathogenic regulatory protein of Vibrio vulnificus and ManNA6P which is a NanR regulator. Further, the present invention relates to a modified NanR protein, a polynucleotide encoding the protein, a vector including the polynucleotide, and a transformant including the vector. Furthermore, the present invention relates to a method for screening a substance regulating interaction between NanR and the transcriptional control region of nan operon which is a gene cluster regulated by NanR, or a substance regulating interaction between NanR and ManNAc-6P, by designing three-dimensional structure of the complex, and to an antibacterial composition including the screened substance.
Abstract translation: 本发明涉及通过结晶作为创伤弧菌的关键致病性调节蛋白NanR的复合物和作为NanR调节剂的ManNA6P而研究的复合物的三维结构。 此外，本发明涉及修饰的NanR蛋白，编码该蛋白的多核苷酸，包含该多核苷酸的载体和包含该载体的转化体。 此外，本发明涉及一种用于筛选调节NanR与NanR调控的基因簇的Nan操纵子的转录控制区之间的相互作用的物质或调节NanR与ManNAc-6P之间的相互作用的物质的方法， 复合物的三维结构，以及包含筛选物质的抗菌组合物。
-
-
-
-
-
-
-
-
-
Search Results
568
records
(took 0.034 seconds)
